Radiopaedia Helpers

Hybrid Imaging Slash

error

"PSMA imaging: PET/CT with intravenous administration of radiolabeled PSMA ligand (commonly ⁶⁸Ga-PSMA-aa or ¹⁸F-DCFPyL)"

Line 8:22 · Hybrid imaging takes a hyphen, not a slash: 'PET/CT'.

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:391 · Hybrid imaging takes a hyphen, not a slash: 'PET/CT'.

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:401 · Hybrid imaging takes a hyphen, not a slash: 'SPECT/CT'.

Isotope Notation

error

"PSMA imaging: PET/CT with intravenous administration of radiolabeled PSMA ligand (commonly ⁶⁸Ga-PSMA-aa or ¹⁸F-DCFPyL)"

Line 8:104 · Write the isotope as symbol-mass, e.g. F-18, not '68Ga'.

"PSMA imaging: PET/CT with intravenous administration of radiolabeled PSMA ligand (commonly ⁶⁸Ga-PSMA-aa or ¹⁸F-DCFPyL)"

Line 8:131 · Write the isotope as symbol-mass, e.g. F-18, not '18F'.

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:70 · Write the isotope as symbol-mass, e.g. F-18, not '177Lu'.

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:194 · Write the isotope as symbol-mass, e.g. F-18, not '177Lu'.

Units

error

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:70 · Put a space between the number and the unit in '177L'.

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:194 · Put a space between the number and the unit in '177L'.

List Punctuation

error

"Of note, Lutetium-177 vipivotide tetraxetan was approved by the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) in 2022."

Line 12:158 · Do not put full stops at the end of a list item.

"Actinium-based PSMA therapies are not yet approved by these agencies - research studies are ongoing."

Line 13:100 · Do not put full stops at the end of a list item.

List Caps

warning

"Of note, Lutetium-177 vipivotide tetraxetan was approved by the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) in 2022."

Line 12:8 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.

"Actinium-based PSMA therapies are not yet approved by these agencies - research studies are ongoing."

Line 13:8 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.

"Lutetium-177 vipivotide tetraxetan"

Line 22:11 · In general, we don't start a list item with a capital letter. Exceptions are proper nouns.

Acronyms

warning

"Of note, Lutetium-177 vipivotide tetraxetan was approved by the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) in 2022."

Line 12:79 · 'FDA' has no definition. Spell it out if it's unfamiliar to the audience.

Personal Names

warning

"Of note, Lutetium-177 vipivotide tetraxetan was approved by the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) in 2022."

Line 12:84 · Titles and initials take no full stops: 'U.S. '.

Semicolons

suggestion

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:137 · Use semicolons judiciously.

"PSMA-targeted radioligand therapy: therapeutic radioligands (¹⁷⁷Lu or ²²⁵Ac) bound to PSMA ligands administered; these radioligands emit beta particles (¹⁷⁷Lu) or alpha particles (²²⁵Ac), delivering targeted localised radiation to PSMA-expressing tumour cells; response my be monitored through follow-up PSMA imaging with PET/CT or SPECT/CT"

Line 10:328 · Use semicolons judiciously.

Lint: psma-theranostics